<DOC>
	<DOC>NCT01279720</DOC>
	<brief_summary>Adenosine deaminase deficiency is an inherited disorder that results in severe abnormalities of the immune system and leaves children unable to fight infection. This trial aims to treat adenosine deaminase deficiency patients using gene therapy.</brief_summary>
	<brief_title>Gene Therapy ADA Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>1. Patients who lack a human leukocyte antigen (HLA)genotypically identical bone marrow donor OR phenotypically matched family or unrelated donor AND who show incomplete immune reconstitution on Polyethylene glycolmodified adenosine deaminase (PEGADA) enzyme replacement therapy (defined by absolute CD4+ count &lt;300 cell/mm3 and who remain on immunoglobulin replacement therapy) 2. Diagnosis of ADASCID (Severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA)confirmed by DNA sequencing OR by confirmed absence of &lt;3% of ADA enzymatic activity in peripheral blood or (for neonates) in umbilical cord blood erythrocytes and/or leukocytes or in cultured fetal cells derived from either chorionic villus biopsy or amniocentesis, prior to institution of PEGADA replacement therapy 3. Parental/guardian/patient signed informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Adenosine deaminase deficiency</keyword>
	<keyword>Gene therapy</keyword>
</DOC>